PRNewswire

Editor's Summary:

• New Acer Chromebooks deliver best-in-class management and security features coupled with the power, speed, and new AI capabilities that cloud-based organizations need.
• Acer Chromebook Plus Enterprise 515 boasts a large 15.6-inch display and dedicated numeric keypad ideal for number-intensive applications; Convertible 2-in-1 Acer Chromebook Plus Enterprise Spin 514 ideal for mobile workforces that need the flexibility of notebook-to-tablet input in a... (continue reading...)

New 3D camera seamlessly integrates with SpatialLabs devices, streaming, and video calling platforms; Plus new developer tools made available on SpatialLabs Pro devices

Editor's Summary:

• The Acer SpatialLabs Eyes Stereo Camera is designed for photographers, allowing them to capture and view stereoscopic images in immersive 3D with compatibility with Acer's SpatialLabs suite of devices
• Features 8 megapixels (MP) per eye resolution, built-in selfie mirror, and... (continue reading...)

New TravelMate laptops deliver business-grade experiences with the latest AI, security, and management solutions, in durable thin-and-light chassis designs

Editor's Summary

• New Acer TravelMate laptops are powered by the latest processors with built-in NPUs, Copilot on Windows with dedicated hotkey[1], Trusted Platform Module (TPM) 2.0 security protection and Acer's suite of commercial management solutions
• The Intel Evo™ Edition[2] Acer TravelMate P6 14 brings... (continue reading...)

MILAN, May 31, 2024 /PRNewswire/ -- InSilicoTrials (IST) is honored to have received the AI Startup of the Year award at Startup Grind Global 2024 in Silicon Valley, California. IST won amidst intense competition from 650 startups and was one of only 142 selected to present and demonstrate their innovations. The key factors that led to IST's win were the platform's proven efficiency outcomes (aligned with global regulatory bodies' guidelines), the substantial savings... (continue reading...)

• The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC)1,2
• In both trials, the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including endoscopic improvement** and histologic-endoscopic mucosal improvement,† were met1,2
• UC is a chronic, idiopathic,... (continue reading...)